肌肉骨骼系统的共同研究·授权契约(2016年～2025年)

本报告提供全球生物医药品产业调查分析，提供2016年～2025年的肌肉骨骼系统的共同研究·授权契约476件相关，契约条件等详细资讯。

目录

摘要整理

第1章 简介

第2章 肌肉骨骼系统契约趋势

• 简介
• 过去数年的肌肉骨骼系统合作伙伴契约
• 肌肉骨骼系统合作伙伴契约:各类型契约
• 肌肉骨骼系统合作伙伴契约:各产品部门
• 肌肉骨骼系统合作伙伴契约:各开发阶段
• 肌肉骨骼系统合作伙伴契约:各技术类型
• 肌肉骨骼系统合作伙伴契约:各适应症

第3章 肌肉骨骼系统合作伙伴契约相关财务的契约条件

• 简介
• 肌肉骨骼系统合作伙伴契约相关公开的财务条件
• 肌肉骨骼系统合作伙伴契约的标题金额
• 肌肉骨骼系统契约的预付款
• 肌肉骨骼系统契约的阶段性付款
• 肌肉骨骼系统特许权率

第4章 主要肌肉骨骼系统契约与谈判者

• 简介
• 在肌肉骨骼系统合作伙伴契约领域中最活跃
• 肌肉骨骼系统领域的最活跃的谈判者的清单
• 前几名的肌肉骨骼系统契约(金额)

第5章 肌肉骨骼系统契约文件名录

• 简介
• 合同可取得的肌肉骨骼系统合作伙伴契约

第6章 按肌肉骨骼系统契约:治疗标的

• 简介
• 契约:肌肉骨骼系统治疗标的
• 契约名录
• 契约名录 - 肌肉骨骼系统契约:各企业(A～Z)(2016年～2025年)
• 契约名录 - 肌肉骨骼系统契约:各技术类型(2016年～2025年)
• 契约类型定义
• 关于Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Current Partnering的近几年报告的标题

Musculoskeletal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the musculoskeletal deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 476 musculoskeletal deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of musculoskeletal dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in musculoskeletal dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the musculoskeletal field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in musculoskeletal dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of musculoskeletal deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of musculoskeletal deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in musculoskeletal deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Musculoskeletal Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse musculoskeletal collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Musculoskeletal Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of musculoskeletal trends and structure of deals entered into by leading biopharma companies worldwide.

Musculoskeletal Collaboration and Licensing Deals includes:

• Trends in musculoskeletal dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of musculoskeletal deal records covering pharmaceutical and biotechnology
• The leading musculoskeletal deals by value
• Most active musculoskeletal licensing dealmakers

In Musculoskeletal Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Musculoskeletal Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in musculoskeletal dealmaking

• 2.1. Introduction
• 2.2. Musculoskeletal partnering over the years
• 2.3. Musculoskeletal partnering by deal type
• 2.4. Musculoskeletal partnering by industry sector
• 2.5. Musculoskeletal partnering by stage of development
• 2.6. Musculoskeletal partnering by technology type
• 2.7. Musculoskeletal partnering by therapeutic indication

Chapter 3 - Financial deal terms for musculoskeletal partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for musculoskeletal partnering
• 3.3. Musculoskeletal partnering headline values
• 3.4. Musculoskeletal deal upfront payments
• 3.5. Musculoskeletal deal milestone payments
• 3.6. Musculoskeletal royalty rates

Chapter 4 - Leading musculoskeletal deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in musculoskeletal partnering
• 4.3. List of most active dealmakers in musculoskeletal
• 4.4. Top musculoskeletal deals by value

Chapter 5 - Musculoskeletal contract document directory

• 5.1. Introduction
• 5.2. Musculoskeletal partnering deals where contract document available

Chapter 6 - Musculoskeletal dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by musculoskeletal therapeutic target
• Deal directory
• Deal directory - Musculoskeletal deals by company A-Z 2016 to 2025
• Deal directory - Musculoskeletal deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Musculoskeletal partnering since 2016
• Figure 2: Musculoskeletal partnering by deal type since 2016
• Figure 3: Musculoskeletal partnering by industry sector since 2016
• Figure 4: Musculoskeletal partnering by stage of development since 2016
• Figure 5: Musculoskeletal partnering by technology type since 2016
• Figure 6: Musculoskeletal partnering by indication since 2016
• Figure 7: Musculoskeletal deals with a headline value
• Figure 8: Musculoskeletal deals with upfront payment values
• Figure 9: Musculoskeletal deals with milestone payment
• Figure 10: Musculoskeletal deals with royalty rates
• Figure 11: Active musculoskeletal dealmaking activity since 2016
• Figure 12: Top musculoskeletal deals by value since 2016